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Background: The acquisition of effective Vpu-mediated anti-tetherin activity to promote virion release following
transmission of SIVcpzPtt from central chimpanzees (Pan troglodytes troglodytes) to humans distinguishes pandemic
HIV-1 group M strains from non-pandemic group N, O and P viruses and may have been a prerequisite for their
global spread. Some functional motifs in the cytoplasmic region of HIV-1 M Vpus proposed to be important for
anti-tetherin activity are more frequently found in the Vpu proteins of SIVcpzPtt than in those of SIVcpzPts infecting
eastern chimpanzees (P. t. schweinfurthii), that have not been detected in humans, and SIVgor from gorillas, which is
closely related to HIV-1 O and P. Thus, SIVcpzPtt strains may require fewer adaptive changes in Vpu than SIVcpzPts
or SIVgor strains to counteract human tetherin.
Results: To examine whether SIVcpzPtt may only need changes in the transmembrane domain (TMD) of Vpu to
acquire anti-tetherin activity, whereas SIVcpzPts and SIVgor may also require changes in the cytoplasmic region, we
analyzed chimeras between the TMD of an HIV-1 M Vpu and the cytoplasmic domains of SIVcpzPtt (n = 2), SIVcpzPts
(n = 2) and SIVgor (n = 2) Vpu proteins. Unexpectedly, all of these chimeras were capable of counteracting human
tetherin to enhance virion release, irrespective of the presence or absence of the putative adaptor protein binding
sites and the DSGxxS β-TrCP binding motif reported to be critical for effective anti-tetherin activity of M Vpus. It was
also surprising that in three of the six chimeras the gain of anti-tetherin function was associated with a loss of the
CD4 degradation activity since this function was conserved among all parental HIV-1, SIVcpz and SIVgor Vpu
proteins.
Conclusions: Our results show that changes in the TMD of SIVcpzPtt, SIVcpzPts and SIVgor Vpus are sufficient to
render them active against human tetherin. Thus, several previously described domains in the extracellular region of
Vpu are not absolutely essential for tetherin antagonism but may be required for other Vpu functions.Background
In order to replicate and spread efficiently in their
respective hosts primate lentiviruses have to counteract
a variety of innate host restriction factors that are fre-
quently induced by type I interferons and inhibit viruses at
various steps in their life cycle [1,2]. As a countermeasure,
primate lentiviruses have evolved effective antagonists that* Correspondence: frank.kirchhoff@uni-ulm.de
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from their viral targets [3,4]. Both, the antiviral factors and
their viral antagonists are under strong selection pressure
for diversification [2]. As a consequence, host restriction
factors are highly divergent and frequently counteracted by
viral factors in a species-specific manner. Thus, they may
pose significant hurdles to cross-species transmissions [4].
The genetic barrier for cross-species transmission is
reduced between closely related species because pathogens
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deficiency viruses (SIVs) infecting chimpanzees and
gorillas that represent the direct precursors of human
immunodeficiency virus type 1 (HIV-1) are resistant
against human tripartite motif-containing protein 5
(TRIM5α) [5], which induces untimely uncoating of retro-
viral capsids [6,7]. Furthermore, SIVcpz and (most likely)
SIVgor Vif are capable of antagonizing the human
APOBEC3G orthologue because it is highly homologous to
the corresponding ape proteins [8]. Thus, adaptation of
these SIVs to our closest non-human relatives has already
disarmed two potent human defense factors. In contrast,
primate lentiviruses are unable to counteract the human
tetherin orthologue because it contains a deletion in the
cytoplasmic region that renders it resistant to the accessory
protein Nef, which is used by most SIVs (including SIVcpz
and SIVgor) to counteract tetherin [9-11]. As a conse-
quence, tetherin that inhibits virus release by tethering
nascent virions at the cell surface seems to constitute a
significant barrier to the effective spread of primate lentivi-
ruses in humans [12]. Thus far, only pandemic HIV-1 group
M strains have fully cleared this hurdle by the acquisition
of effective Vpu-mediated anti-tetherin activity [9]. In
comparison, HIV-1 group O and P strains, which resulted
from independent zoonotic transmissions and are closely
related to SIVgor [13,14] have apparently not yet evolved
an effective antagonist of human tetherin [9,15]. Finally,
Vpus of the rare HIV-1 N strains acquired some anti-
tetherin activity in humans, but lost the second key
function of Vpu, i.e. degradation of CD4, the primary
viral receptor [9,16].
Molecular epidemiological studies of SIVcpz in wild-
living chimpanzees throughout central Africa have
shown that only viruses infecting P.t. troglodytes but
not P. t. schweinfurthii apes have crossed the species
barrier to humans [17-19], although SIVcpz infection is
common in both of them [20]. Furthermore, only the
M and N groups of HIV-1 that were transmitted from
central chimpanzees (Ptt) but not group O and P HIV-1
strains that are most closely related to SIVgor, gained
Vpu-mediated anti-tetherin activity during adaptation to
humans [9]. The transmembrane domain (TMD) of Vpu
seems to interact directly with the TMD domain of
tetherin and changes in the TMD were critical for the gain
of anti-tetherin activity of group M and N viruses during
adaptation to humans [9-11,16]. Furthermore, it has been
reported that certain tyrosine- (Yxxφ) and dileucine-based
(E/DxxxLL/I/V/M) sorting motifs in the cytoplasmic
domain of Vpu are critical for effective tetherin antagonism
by M Vpus [21-24]. Sequence analyses revealed that these
motifs are conserved in most SIVcpzPtt Vpus but absent in
SIVcpzPts Vpus [20]. Thus, these findings raised the possi-
bility that the Vpu proteins of SIVcpzPtt strains might only
have to acquire alterations in the TMD of Vpu to evolveanti-human tetherin activity, whereas those of SIVcpzPts
and SIVgor would also need changes in the cytoplasmic
region [20]. To examine this possibility, we generated
chimeric proteins between the TMD of the HIV-1 M
NL4-3 Vpu and the cytoplasmic regions of SIVcpzPtt,
SIVcpzPts and SIVgor Vpus. Unexpectedly, we found
that all of these chimeric proteins were potent tetherin
antagonists, although some of them lack functional
domains thought to be important for potent counteraction
of tetherin by group M Vpus.
Results
In the present study, we examined whether differential
adaptive hurdles of SIVcpz Vpu could explain why only
one of two infected subspecies of chimpanzees served as
a zoonotic reservoir for humans and why HIV-1 groups
O and P that are most closely related to SIVgor [25]
failed to acquire Vpu-mediated anti-tetherin activity
(Figure 1A). As shown in Figure 1B, several domains
reported to be important for the anti-tetherin activity of
HIV-1 M Vpus, such as a putative AP-binding Yxxφ
motif [22,26], D/ExxxLL/I/V/M endocytosis motifs [21]
and a DSGxxS ß-TrCP interaction domain [26-28], are
preserved in the SIVcpzPtt MB897 and EK505 Vpus, but
not in those derived from the SIVcpzPts TAN3 and
ANT strains. The SIVgor CP2139 and BQ664 Vpus do
not contain a Yxxφ motif adjacent to their TMD and the
DSGxxS domain is changed to DEGxxS (Figure 1B).
Notably, it has been shown that a phosphorylated serine
residue may be mimicked by an acidic residue [29]
suggesting that the latter motif may still be capable of
interacting with ß-TrCP. To examine whether the
SIVcpzPtt Vpus may only require alterations in the
TMD to counteract human tetherin, whereas the
SIVcpzPts and SIVgor Vpus may need additional changes
in cytoplasmic part (CP), we generated a set of chimeras
between the TMD of the HIV-1 M NL4-3 Vpu, which is a
well characterized antagonist of human tetherin, and the CP
of these SIV Vpus (Figure 1B; Additional file 1: Table S1).
All wild-type and chimeric Vpus were expressed at detect-
able albeit highly variable levels in transfected 293T and
HeLa cells except for the SIVcpzPts TAN3 Vpu (Figure 2A).
The latter was difficult to detect by Western blot, although
this protein efficiently degrades CD4 [9]. It is known that the
functional activity of Vpu proteins does not always correlate
with their in vitro expression levels detected by Western
blot, possibly because they aggregate and/or remain
associated with the insoluble membrane fraction [9,16].
To examine the ability of these wild-type and chimeric
Vpu proteins to reduce cell surface expression of tetherin,
we transfected 293T cells with constructs co-expressing the
various Vpus and eGFP together with a construct express-
ing human tetherin and analyzed them by flow cytometry.

























Figure 1 Zoonotic transmissions of SIVs from apes to humans and adaptive changes in Vpu and Nef functions. (A) The Nef proteins of
SIVcpz and SIVgor down-modulate CD4 from the cell surface and counteract tetherin in their non-human hosts. Upon cross-species transmission
of SIVcpz and SIVgor to humans, Nef-mediated tetherin antagonism was disrupted by a unique deletion in the cytoplasmic tail of the human
tetherin orthologue. Subsequently, Vpu evolved to counteract tetherin during the emergence of pandemic HIV-1 M strains. In contrast, HIV-1 O
and P Vpus did not gain anti-tetherin activity. Finally, Vpus of group N viruses evolved some activity against human tetherin but lost their ability
to degrade CD4. The arrows indicate activity or cross-species transmissions. Grey indicates antagonism of tetherin or CD4 by one and light grey
by two viral factors. (B) Alignment of SIVcpz and SIVgor Vpu amino acid sequences. The HIV-1 NL4-3 Vpu sequence is shown on top for
comparison. The AxxxAxxxAxxxW residues in the TMD that are important for anti-tetherin activity of M Vpus, a putative Yxxφ motif, two
phosphorylation sites in the DSGxxS ß-TrCP interaction site, and an E/DxxxLL/I/V/M motif involved in targeting of tetherin for endosomal
degradation are indicated. The consensus DSGxxS ß-TrCP interaction site is highlighted in green and sites containing mutations of the serines to
acidic residues in light blue. Dashes indicate gaps introduced to optimize the alignment.
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results [9], the NL4-3 Vpu significantly reduced the levels
of tetherin expression at the cell surface, whereas the
wild-type SIVcpz and SIVgor Vpus were largely inactive
(Figure 2B, 2C). The TMD of the NL4-3 Vpu significantly
increased the capability of the MB897 and BQ664 Vpus to
reduce the surface levels of tetherin in transfected 293T
cells, but had only little (if any) effect on the functional
activity of the EK505, TAN3, ANT and CP2139 Vpus
(Figure 2B, 2C). To test whether the latter was the result of
artificial over-expression of tetherin, we examined the of
the various wild-type and chimeric Vpu proteins effects on
the surface expression of endogenously produced tetherin
in HeLa cells (Figure 2D, Additional file 2: Figure S1). Wefound that the Vpu-dependent reduction of tetherin surface
expression was more pronounced in HeLa than in 293T
cells, e.g. the NL4-3 Vpu achieved an 85% reduction in the
former but only 60% in the latter (Figure 2B-D). This
difference in tetherin down-modulation efficiency is
most likely a consequence of the higher expression
levels in transiently transfected 293T cells (Figure 2E).
Unexpectedly, replacement of the SIVcpz and SIVgor
Vpu TMD by that of HIV-1 resulted in a reduction of
tetherin surface expression in HeLa cells of 60% to 90%
(Figure 2D). Even more surprisingly, the chimera between
NL4-3 and ANT Vpu (NL-AN) showed the highest activity,
although it lacks the Yxxφ, DSGxxS and E/DxxxLL/I/
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Figure 2 Down-modulation of human tetherin by chimeras between HIV-1 and SIVcpz/gor Vpus. (A) Expression of wild-type Vpu proteins
and chimeras between the TMD of HIV-1 NL4-3 Vpu and the CP of SIVcpz or SIVgor Vpus. 293T cells were transfected with expression plasmids
encoding the indicated AU1-tagged Vpus and eGFP. Mock transfected cells were used as negative control. ß-actin and eGFP expression levels
were analyzed to control for loading and transfection efficiency, respectively. For HeLa cells two different western blots are shown to allow
comparison of Vpu signal intensities (middle) and to show that all Vpus can be detected after long exposure times (bottom). (B) FACS analysis of
293T cells co-transfected with a vector expressing tetherin and plasmids expressing eGFP alone or together with the indicated vpu allele. The
range of eGFP expression levels used to calculate receptor down-modulation and the mean fluorescence intensities (MFI) are indicated. (C, D)
Vpu-dependent reduction of tetherin surface expression in (C) 293T and (D) HeLa cells. Shown are the levels of receptor cell surface expression
relative to those measured in cells transfected with the eGFP only control vector (100%). Data represent average values (±SEM) derived from
three or more experiments. (E) Expression of tetherin in untransfected 293T or HeLa cells and in 293T cells transfected with a construct
expressing human tetherin (293T teth). (F) Correlation between the levels of tetherin expression on 293T and HeLa cells expressing wild-type or
chimeric Vpus proteins.
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imperfectly, because some Vpus were substantially more
active in the latter cell type (Figure 2F).
To determine the ability of wild-type and chimeric
SIVcpz and SIVgor Vpus to promote virus release in the
presence of tetherin, we co-transfected 293T cells with a
vpu defective HIV-1 NL4-3 construct, pCGCG vectors
expressing AU1-tagged versions of Vpu and different
doses of human tetherin. In contrast to the parental
SIVcpz and SIVgor proteins, all chimeras were capable
of promoting infectious virus release (Figures 3A). The
chimera between the HIV-1 TMD and the SIVgor
BQ664 CP (NL-BQ) increased infectious virus release in
both 293T and HeLa cells almost as efficiently as thecontrol NL4-3 Vpu and was substantially more effective
than the chimeras between HIV-1 and SIVcpzPtt Vpus
(NL-MB, NL-EK) (Figures 3A, 3B). This was surprising
because in contrast to the SIVcpzPtt MB897 and EK505
Vpus, the cytoplasmic part of the SIVgor BQ664 Vpu
contains substitutions in the DSGxxS motif (DEGYES)
and lacks a putative Yxxφ motif (Figure 1B). These
results were confirmed by measuring the quantity of
fectious virus and p24 release in the culture supernatant
of HeLa cells co-transfected with proviral HIV-1 and
Vpu expression constructs (Figures 3C to E). All Vpus
that promoted infectious virus release in transiently
transfected 293T cells were also active in HeLa cells
(Figure 3F) and most Vpu proteins that reduced
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Figure 3 Enhancement of virus release in the presence of human tetherin by chimeras between HIV-1 and SIVcpz/gor Vpu. (A)
Infectious virus yield from 293T cells co-transfected with an HIV-1 NL4-3 Δvpu construct and vectors expressing the indicated vpu alleles in
combination with various quantities of plasmids expressing tetherin. Shown are average values derived from triplicate infections of TZM-bl
indicator cells relative to those obtained in the absence of tetherin (100%). The mean of three independent experiments is shown. The results
were verified by measuring the cell-free p24 levels by ELISA. (B) Infectious virus yield from 293T cells co-transfected with the proviral HIV-1 NL4-3
Δvpu construct (4 μg), pCGCG vectors expressing the indicated vpu alleles (1 ng) and a plasmid expressing human tetherin (50 ng). Shown are
average values (±SEM) derived from three independent experiments each involving triplicate infections of TZM-bl indicator cells. (C, D) Detection
of (C) infectious HIV-1 and (D) p24 antigen in the supernatant of HeLa cells that express tetherin endogenously and were co-transfected with
HIV-1 NL4-3 Δvpu and the indicated Vpu expression constructs. Data represent average values (±SEM) derived from three experiments. (E-G)
Correlation between infectious virus release from HeLa cells and (E) p24 release, (F) infectious virus release from 293T cells and (G) tetherin cell
surface expression levels of HeLa cells. (H) Correlation of infectious virus release and tetherin surface expression levels of 293T cells.
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http://www.retrovirology.com/content/10/1/32tetherin surface expression also enhanced virion release
(Figure 3G, 3H).
To further analyze the unexpected activity of the
chimeric Vpus against human tetherin, we next performed
microscopic analyses in HeLa cells to examine their effecton the subcellular localization of this restriction factor. In
the absence of Vpu and in cells expressing wild-type
SIVcpzPtt, SIVcpzPts and SIVgor Vpu proteins, tetherin
co-localized with the trans-Golgi network (TGN) marker
TGN46 but was also present at the cell surface (Figure 4).






























































































Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Cellular localization of tetherin in the presence of various Vpu proteins. Confocal immunofluorescence images of HeLa cells
transfected with constructs expressing the indicated Vpu variants. Two days post-transfection, cells were fixed and permeabilized for intracellular
staining of tetherin (red), Vpu (blue) and the TGN (green). Images show representative confocal acquisitions of at least 40 transfected cells
investigated. Tetherin was located at the cell surface in cells transfected with constructs expressing the parental SIVcpz and SIVgor Vpus but not
in cells expressing chimeras containing the TMD of the NL4-3 Vpu. Cellular localization was determined by microscopic examination and by
analysis of the Vpu, tetherin and TGN signal intensities throughout the cells (right panel). The regions utilized to generate the profile plots are
indicated by the arrows. White circles indicate the position of the plasma membrane.
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at the cell surface as effectively as the wild-type NL4-3 Vpu
(Figure 4). Thus, the results of the microscopic analyses
confirmed that the HIV-1 TMD SIVcpz/gor CP chimeras
are effective tetherin antagonists that promote effective
virion release by sequestering the restriction factor away
from the cell surface. Our results further suggest that
co-localization of Vpu and tetherin in the TGN may be
required but not sufficient for tetherin antagonism.
Another well established function that is conserved
among all primate lentiviral Vpus, except for those of
HIV-1 group N strains [9,16], is the ability to degrade
the CD4 receptor [30-32]. To determine whether the
Vpu chimeras were active against CD4, we co-transfected
293T cells with vectors co-expressing Vpu and eGFP
(or eGFP alone for control) together with a CD4 expression
construct. In the absence of Vpu, cells expressed high levels
of CD4 and eGFP (Figure 5A, Additional file 3: Figure S2).
All wild-type HIV-1, SIVcpz and SIVgor Vpu proteins
markedly reduced CD4 cell surface expression, whereas
several Vpu chimeras were poorly active (Figure 5A).
Quantitative analyses showed that the parental Vpus
usually reduced CD4 cell surface expression by more than
80%, whereas the NL-MB, NL-EK and NL-BQ chimeras
only achieved 20% to 50% reduction (Figure 5B). Notably,
the chimeras between the HIV-1 Vpu TMD and the
SIVcpzPts TAN3 and ANT as well as SIVgor CP2139 CPs
of Vpu maintained most of their anti-CD4 activity
(Figure 5B). Analysis of HeLa cells transfected with CD4
expression constructs and of TZM-bl cells stably express-
ing CD4 (Additional file 3: Figure S2) confirmed these
results (Figure 5C-F). The effects were generally weaker
in TZM-bl cells than in transiently transfected 293T and
HeLa cells (Figure 5B-D). This is most likely due to the
fact that Vpu mediates efficient degradation of intracellu-
lar CD4 but is unable to remove CD4 molecules from the
surface that were already at the plasma membrane prior
to transfection [27,30-32]. In 293T cells, we observed a
significant inverse correlation between the effect of the
panel of Vpu protein analyzed on tetherin and CD4
surface expression (Figure 5G). The same trend was found
in HeLa cells but failed to reach significance (Figure 5H)
because the NL-AN and NL-CP chimeras reduced the
surface expression of both receptors (Figures 2D and 5C).
These results suggest that the acquisition of changes inthe TMD of Vpu that confer anti-tetherin activity may
have detrimental effects on the CD4 degradation activity
in the context of some SIVcpz and SIVgor vpu alleles.
Vpu interacts with the cytoplasmic part of CD4 and
binds ß-TrCP to recruit an E3 ubiquitin ligase complex
to CD4 thereby inducing its degradation by cellular
proteasomes [27]. Effective CD4 degradation by M Vpus
requires a functional DSGxxS β-TrCP target motif,
where the serines need to be phosphorylated to allow
efficient recruitment of β-TrCP [31,32]. We have previously
shown that SIVcpz and SIVgor Vpus are highly active
against CD4 [9], although the DSGxxS motif is frequently
altered (e.g. to DSAIEE or DEGYES) and contains only a
single putative phosphorylation site (Figure 1B). To
examine whether the wild-type and chimeric Vpus are
capable of interacting with ß-TrCP, we fused the
N-terminal fragment of the click beetle luciferase to the
C-terminus of Vpu, and the C-terminal fragment of this
luciferase to the N-terminus of ß-TrCP (Figure 6A). If
Vpu and ß-TrCP interact, functional luciferase is
assembled [33]. The interaction of ß-catenin and ß-TrCP
served as positive control [33]. We found that the
wild-type HIV-1 and SIVcpz or SIVgor Vpus interacted
with ß-TrCP, although the detectable levels of luciferase
reporter activity varied (Figures 6A, Additional file 4:
Figure S3A). In agreement with published data
[28,32,34,35], mutations in the DSGxxS motif of the
NL4-3 Vpu (S52A/S56A or G53D) significantly reduced
this interaction. The ANT and BQ664 Vpus that
contained alterations in the β-TrCP binding site showed
weaker interaction than the MB897 Vpu (Figure 6A,
Additional file 4: Figure S3A), which has the consensus
DSGxxS motif. However, all of them were highly effective
in reducing CD4 cell surface expression (Figure 5).
Most importantly, exchanges of the TMD had no
significant effect on the interaction of Vpu with ß-TrCP
(Figure 6A, Additional file 4: Figure S3A). Thus, reduced
ß-TrCP binding was not the reason for the reduced
anti-CD4 activity of some chimeric Vpus.
Next, we used the click beetle complementation assay
to examine whether replacement of the TMD of SIVcpz
or SIVgor Vpus may affect their ability to bind CD4. We
found that all Vpus resulted in increased (albeit variable)
levels of luciferase reporter activity compared to ß-catenin,
which has not been shown to interact with CD4. This
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Figure 5 Modulation of CD4 by chimeras between HIV-1 and SIVcpz/gor Vpus. (A) FACS analysis of 293T cells co-transfected with a CD4
expression vector and pCGCG plasmids expressing eGFP alone (eGFPonly) or together with the indicated vpu alleles. A construct expressing NL4-3 Vpu
was used as a positive control. (B-D) Levels of CD4 surface expression in (B) 293T, (C) HeLa and (D) TZM-bl cells in the presence of the indicated vpu
alleles are compared to those measured in the absence of Vpu (100%). Values give averages (±SEM) derived from three to five independent experiments.
The same ranges of eGFP expression were used in all calculations. (E, F) Correlation between CD4 cell surface levels on 293T and (E) HeLa or (F) TZM-bl
cells. (G, H) Correlation between CD4 and tetherin cell surface levels on (G) 293T cells and (H) TZM-bl and HeLa cells.
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(Figure 6B, Additional file 4: Figure S3B). Mutations in the
ß-TrCP binding site of the NL4-3 Vpu increased the signal
intensities because the binding of ß-TrCP and subse-
quently CD4 luciferase reporter construct degradation
was impaired (Figure 6B, Additional file 4: Figure S3B).
Replacement of the TMDs of the MB897, ANT and
BQ664 Vpus by that of the NL4-3 Vpu had differential
and modest effects on luciferase activity. To examine
whether some of these differences were the result of an
altered interaction or Vpu-mediated degradation of the
CD4 luciferase reporter construct, we repeated the inter-
action assay in the presence of a trans-dominant negative
mutant of ß-TrCP1 (TrCP1ΔFbox). This mutant still
binds Vpu via WD repeats but lacks the Fbox, and thus
fails to recruit the E3 ubiquitin ligase complex forproteasomal degradation of CD4 [32]. In the presence of
the TrCP1ΔFbox mutant, all Vpu chimeras resulted in
similar or moderately increased (NL-MB) levels of luciferase
reporter activities compared to the respective wild-type
SIVcpz and SIVgor Vpus proteins (Figure 6C, S3C)
suggesting that the exchange of the TMD motif did not
disrupt CD4 binding. Thus, the NL-MB and NL-BQ Vpu
chimeras were poorly active in reducing CD4 cell surface
expression (Figure 5), although they were efficiently
expressed (Figure 2A) and capable of interacting with both
ß-TrCP and CD4 (Figure 6, Additional file 4: Figure S3).
Discussion
In the present study, we show that the Vpu proteins of
six SIVcpzPtt, SIVcpzPts and SIVgor strains became

























































































































































































































Figure 6 Interaction of chimeras between HIV-1 and SIVcpz/gor
Vpus with ß-TrCP and CD4. (A) Interaction of Vpu with ß-TrCP. 293T
cells were transfected with equal amounts of plasmids expressing ß-TrCP
N-terminally fused to the C-terminal fragment of click beetle green (CBG)
and Vpu C-terminally fused to the N-terminal fragment of CBG. ß-catenin
served as positive control. After 48 h, click beetle luciferase activity was
determined in living cells by addition of D-luciferin and quantification of
bioluminescence. Values represent means (±SEM) derived from five
independent experiments. (B) Interaction of Vpu with CD4. 293T cells
were transfected with plasmids expressing CD4 C-terminally fused to the
C-terminal fragment of CBG and Vpu C-terminally fused to the N-
terminal fragment of CBG and interaction efficiencies were determined
as described in the methods section. (C) To exclude a bias caused by
Vpu-mediated degradation of CD4, a dominant negative mutant of
β-TrCP1 isoform 2 lacking the F-box (amino acids 141–193) was
co-transfected in a control experiment. This mutant still binds Vpu but
lacks the Fbox domain and thus fails to recruit the E3 ubiquitin ligase
complex. Values represent means (±SEM) derived from three to four
independent experiments.
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domain of HIV-1 Vpu interacts with human tetherin
[24,34,36] and recent data suggest that this interaction
is sufficient for some anti-tetherin activity [16,21,26].
Efficient counteraction of tetherin by M Vpus, however,
also requires several cytoplasmic domains [21,22,26,28,35].
It has been suggested that the absence of these motifs
contributes to the lack of anti-tetherin activity of O Vpus
[26] and may explain the poor activity of group N Vpus
against human tetherin [16]. The Vpu proteins of many
SIVcpz and SIVgor strains, in particular those from
SIVcpzPts strains, lack the canonical functional motifs.
Thus, it came as a surprise when the majority of chimeric
Vpus were almost as effective in reducing cell surface
expression of tetherin and in promoting virus release as the
group M NL4-3 Vpu. Even more strikingly, the most active
chimeras were not the ones between HIV-1 and SIVcpzPtt
Vpus that contained the canonical Yxxφ, E/DxxxLL/I/V/M
and DSGxxS β-TrCP binding motifs, but those between
HIV-1 and SIVcpzPts or SIVgor Vpus that lacked most or
all of these putative domains [20] (Figure 1B). These results
show that the presence or absence of “binding motifs”
important for effective tetherin antagonism by M
Vpus cannot be used to predict the functionality of
the cytoplasmic domain of SIVcpz and SIVgor Vpus. The
data also suggest that most SIVcpz and SIVgor Vpus,
regardless of their genetic diversity, require only changes in
their TMD to become active against human tetherin.
Since SIVcpz and SIVgor clearly use Nef to counteract
the tetherin restriction in their natural ape hosts [9], it
may seem striking that the cytoplasmic domains of their
Vpu proteins fulfill the requirements to antagonize tetherin.
The vpu gene is believed to have originated in a precursor
of SIVs that infects guenons (SIVgsn/mus/mon), which
subsequently recombined with an SIV strain that infects
red-capped mangabeys (SIVrcm) to generate SIVcpz
[37,38]. The Vpus from current SIVgsn, SIVmus and
SIVmon strains are all capable of counteracting the
tetherin orthologue of their cognate host species [9]. Thus,
the Vpu that SIVcpz received from the precursor of the
SIVgsn/mus/mon lineage was most likely a functional
tetherin antagonist. However, due to sequence variations
in the transmembrane portion of Vpu, tetherin is
counteracted in a species-specific manner and subse-
quently Nef and not Vpu evolved to become an effective
tetherin antagonist in chimpanzees [9]. It is tempting to
speculate that the cytoplasmic domain of Vpu maintained
the requirements for counteracting tetherin because the
sequence motifs in Vpu that enable proper subcellular
localization and/or are involved in the recruitment of the
ubiquitination/degradation machinery are also critical for
CD4 degradation and (possibly) for other Vpu activities,
such as down-modulation of the natural killer cell ligand
NTB-A and the lipid-antigen presenting protein CD1d
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for several functions will be preserved even if one func-
tion is lost. Indeed, recent data have shown that just
two amino acid changes are sufficient to render HIV-1
Nef active against chimpanzee tetherin, suggesting that
other functional constraints keep Nef “ready” to regain
this function [42].
The results of the present study further illustrate the
functional plasticity of the viral accessory proteins. It
seems clear that several domains that may be critical for
full activity of M Vpus are not required for effective
tetherin antagonism by chimeric Vpu proteins. Thus, the
functional relevance of some cytoplasmic domains in
Vpu seems to be context dependent. Similarly, we have
previously observed that some SIV or HIV-2 Nef
proteins are fully functional, although they lack some of
the domains reported to be critical for HIV-1 Nef
function [43,44]. It is often difficult to assess whether
the required functional interactions with cellular factors
are performed by different regions of the viral proteins
or whether the sequence variations are tolerated such
that the mutated domains remain active. For example, it
has been reported that phosphorylation of both serines in
the HIV-1 DSGxxS domain is essential for Vpu-mediated
degradation of CD4 [45]. However, a phosphorylated
serine residue may be mimicked by an acidic residue [29].
For example, SIVgor Vpus that contain a DEGxxS
domain interact with ß-TrCP and downregulate CD4 [9].
Furthermore, some Vpu proteins that do not contain the
Yxxφ and E/DxxxLL/I/V/M motifs in their cytoplasmic
region may use different domains to interact with cellular
trafficking or endocytosis motifs. For example, a NPxY
(or FxNPxY or FxNPxF) motif is found in many SIVcpz
and most HIV-1 O Vpus. It is known that this tyrosine
motif allows other type I transmembrane proteins
(e.g. the LDL and insulin receptors) to recruit AP-2
[46-48], but its relevance for Vpu function remains to be
investigated. In either case, our results indicate that the
presence or absence of specific sequence motifs in lentiviral
accessory proteins do not necessarily predict their
functional integrity.
Our results show that it is difficult to predict the
changes required for a gain of anti-tetherin activity of
SIVcpz or SIVgor Vpus based on results obtained using
M Vpus because the effect of sequence alterations is
often context dependent. While our data indicate that
SIVcpzPtt, SIVcpzPts and SIVgor Vpus may require
mainly mutations in their TMDs to acquire significant
anti-tetherin activity, they do not allow to estimate
which and how many amino acid substitutions are
required for optimal adaptation. For example, the adaptive
changes in the TMD that allow HIV-1 group M and N
Vpus are overlapping, but distinct [16,49]. Thus, our
findings do not refute the previously suggested possibilitythat SIVcpzPtt may on average require fewer adaptive
changes than SIVcpzPts strains to become functional in
humans [20].
To avoid possible artifacts due to over expression of
tetherin, we examined the effects of Vpu in both transiently
transfected 293T cells and in HeLa cells, which express
tetherin endogenously. In HeLa cells, the effects of the
various wild-type and chimeric Vpus on the reduction of
tetherin cell surface expression and virus release correlated
significantly (Figure 3G). However, the effects of Vpu on
cell surface expression of tetherin were weaker in 293T cells
and some Vpu chimeras clearly reduced tetherin surface
expression in HeLa cells, but failed to exert a significant
effect in 293T cells (Figure 2C, 2D). The reasons for these
discrepancies remain unknown, but may involve higher
expression levels (Figure 2E) as well as different glycosyla-
tion patterns of tetherin. Nonetheless, these results suggest
that potent anti-tetherin effects can be monitored in 293T
cell-based over-expression assays, but weaker activities
against tetherin may be missed.
In some cases, a gain of anti-tetherin activity by the
Vpu chimeras was associated with a significant loss of
the CD4 degradation function. This came as a surprise
because all parental Vpus were active against CD4 and
the chimeras thus contained all functional domains
required for this activity. The inverse correlation between
both functions was dependent on the context of the
specific SIVcpz or SIVgor vpu alleles utilized to generate
the Vpu chimeras. Specifically, chimeras between the
TMD of HIV-1 Vpu and the CP of SIVcpzPtt MB897 and
EK505 or SIVgor BQ664 Vpu (NL-MB, NL-EK, NL-BQ)
were poorly active against CD4, whereas the remaining
three chimeras (NL-TA, NL-AN and NL-CP) potently
suppressed CD4 cell surface expression (Figure 5). Thus,
the acquisition of TMD changes facilitating tetherin inter-
action and counteraction can come at a cost, i.e., the loss
in the CD4 degradation function. It remains a matter of
speculation whether this may explain the loss of the CD4
degradation activity of group N Vpus [9]. The reasons for
the loss of CD4 down-regulation function in some Vpu
chimeras also remain to be determined as they contain
all known interaction domains and bind both CD4 and
ß-TrCP molecules (Figure 6). Furthermore, efficient
expression and anti-tetherin activity of these Vpu chimeras
argue against major structural defects. It thus seems clear
that the TMD and CP of Vpu must interact in some way
for full functionality of the protein.
Conclusions
A better understanding of the adaptive barriers that
primate lentiviruses have to overcome to spread efficiently
in humans is essential to assess the potential risk of future
pandemics and may help to develop new preventive
strategies. Previous results suggest that effective tetherin
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ive spread of pandemic HIV-1 M strains [12,50] and that
easier adaptability of Vpu to humans may explain why
only certain SIVcpz and SIVgor strains have become
new human pathogens [20]. We show here that Vpus
from all major SIVcpz and SIVgor lineages require only
changes in their TMD to acquire activity against human
tetherin. Thus, these ape viruses seem to be more prone
to acquire anti-tetherin activity in humans than previously
anticipated and it is thus surprisingly that group O and N
Vpus have not yet evolved anti-tetherin activity during
adaptation to humans. One possible reason for this is that
these changes may compromise the CD4 degradation
function of Vpu, which may help to explain the loss of the
latter activity during adaptation of HIV-1 group N to
humans. Our results illustrate that the plasticity and
multi-functionality of primate lentiviral accessory proteins
makes reliable predictions concerning their zoonotic
potential difficult. Notably, the same multi-functionality
may also allow primate lentiviruses to acquire new antago-
nisms, because functions for endocytosis or proteasomal
degradation are already in place.
Methods
Expression vectors and proviral constructs
Bi-cistronic CMV-promoter-based pCGCG vectors co-
expressing Vpu or tetherin and the enhanced green
fluorescent protein (eGFP) or dsRed2, respectively,
have been described previously [9]. The vpu alleles
were not codon optimized. Splice-overlap-extension
PCR was used to introduce an AU1-tag as well as XbaI
and MluI restriction sites flanking the reading frames.
The PCR fragments were cloned into the pCGCG vector
using standard cloning techniques. To inhibit β-TrCP
mediated recruiting of the E3 ubiquitin ligase to Vpu,
a dominant negative mutant of β-TrCP1 isoform 2
lacking the Fbox (amino acids 141–193) was synthesized
(Genscript, Piscataway, USA) and cloned into the pCGCG
vector co-expressing dsRed2 via an IRES [16]. All PCR-
derived inserts were sequence confirmed. A vpu deleted
mutant of a CCR5-tropic HIV-1 NL4-3 proviral derivative
[51] was used to determine the effect of various Vpus on
infectious virus release following complementation in trans.
Cell culture
293T and HeLa cells were maintained in Dulbecco
modified Eagle medium (DMEM) supplemented with 10%
heat-inactivated fetal bovine serum, 350 μg/ml L-glutamine,
120 μg/ml streptomycin sulfate and 120 μg/ml penicillin.
TZM-bl cells, a HeLa cell line derivative that expresses
large amounts of CD4, CCR5 and CXCR4 and contain
the ß-galactosidase gene under the control of the HIV-1
promoter [52-54] were kindly provided by Drs. Kappes and
Wu and Tranzyme Inc. through the NIH AIDS ReagentProgram and were kept in DMEM supplemented as
described above.
Western blot
To monitor Vpu expression, HeLa cells were transfected
with 5 μg of the expression constructs. Two days post-
transfection cells were harvested, lysed in M-PER buffer
(ThermoScientific) containing 1% SDS and a protease
inhibitor cocktail (Roche) and cell lysates were separated
in 10% SDS-PAA gels in a Tris-Tricine buffer system.
After gel electrophoresis, proteins were transferred onto
PVDF membranes and probed with anti-AU1 antibody
(Covance, MMS-130P). For internal controls, blots were in-
cubated with antibodies specific for eGFP (290–50, Abcam)
and β-actin (8227–50, Abcam). Subsequently, blots were
probed with anti-mouse or anti-rabbit IRDye Odyssey
antibodies (926–32210, 926–32221) and proteins detected
using a LI-COR Odyssey scanner.
Flow cytometric analysis
To determine the effect of Vpu on tetherin and CD4 cell
surface expression, 293T were transfected in 6-well
plates by the calcium phosphate method as described
previously [55] and HeLa cells using Lipofectamine LTX
reagent (Invitrogen) with 1 μg of a tetherin (for 293T cells)
or CD4 (for 293T and HeLa cells) expression vector
and 5 μg of pCGCG constructs expressing eGFP alone
(as control) or together with Vpu. Two days post-
transfection, tetherin or CD4 expression was examined
by FACS analysis, as described previously [56]. An
allophycocyanin (APC)-conjugated anti-human CD4
antibody (Invitrogen; MHCD0405) was used for stain-
ing of surface CD4. For staining of surface tetherin an
unconjugated anti-tetherin antibody (eBioscience) and
an APC-conjugated secondary anti-mouse antibody
(Invitrogen, A865) were used. Fluorescence of stained
cells was detected by two-color flow cytometry and
Vpu-mediated tetherin or CD4 down-modulation was
calculated as described previously for the functional
analysis of nef alleles [37]. Briefly, for exogenously
expressed proteins, the mean fluorescence intensity
(MFI) obtained for cells transfected with the control
construct expressing only eGFP was compared to the
MFI obtained for cells co-expressing Vpu and eGFP to
determine the efficiency of tetherin or CD4 down-
regulation. For endogenously expressed proteins, the
MFI of untransfected cells (eGFP negative) was compared
to the MFI of transfected cells (eGFP positive). The
transfection of the control construct expressing only
eGFP served as reference.
Virus release assays
To determine the capability of Vpu to antagonize
tetherin, 293T or HeLa cells were seeded in six-well
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eGFP, 1 μg Vpu expression plasmid and (for 293T cells)
different amounts of a tetherin expression vector
(6.25, 12.5, 25, 50, 125 and 250 ng). Two days post-
transfection, supernatants were harvested and analyzed for
infectious virus release by a 96-well infection assay on
TZM-bl indicator cells [55] and the release of p24 antigen
by ELISA as described previously [9].
Microscopy
HeLa cells were transfected using Lipofectamine LTX
Reagent (invitrogen) with pCGCG Vpu_AU1 constructs
and stained 24 hours post-transfection. Briefly, cells were
fixed with 4% PFA, blocked with BSA and surface
tetherin was stained with an anti-tetherin antibody
(eBioscience) and a secondary antibody conjugated to
Alexa FluorW 647 (Invitrogen). Cells were then perme-
abilized with 0.5% saponin. After blocking with BSA,
Vpu, tetherin and TGN46 were stained with an anti-AU1
(Covance), anti-tetherin (eBioscience) and anti-TGN46
(Serotec) antibody, respectively. Secondary antibodies con-
jugated to Alexa FluorW 568, Alexa FluorW 647 and Alexa
FluorW 488 were used for detection (Invitrogen). A confocal
microscope (LSM 710, Zeiss) with the corresponding soft-
ware (Zeiss Zen Software, 2010) was used for analysis.
Click beetle assay
The click beetle luciferase heteroprotein fragment
complementation assay allows the real-time analysis of
protein-protein interactions in living cells [33]. pCBG-
C_ß-TrCP1 and pß-catenin_CBG-N constructs encoding
the N- or C-terminal fragment of click beetle green
(CBG) were kindly provided by Piwnica-Worms. SalI
and BamHI restriction sites were added to the vpu
alleles by PCR and standard cloning techniques were
used to insert the Vpu alleles into the pCBG-C vector
replacing the ß-catenin gene. Splicing by overlap exten-
sion PCR (SOE-PCR) was used to fuse the C-terminal
CBG-fragment to the C-terminus of human CD4. The
ß-TrCP1_CBG-C gene was replaced by the CD4_CBG-C
fusion gene via HindIII and XbaI digestion. The lucifer-
ase assay was essentially performed as described before
[33]. Briefly, 293T cells in white 96-well plates with clear
bottom were transfected with equal amounts of the click
beetle green constructs. 48 hours after transfection the
cells were washed once and then incubated in MEBSS
buffer (Modified Eagle’s balanced salt solution: 144 mM
NaCl, 5.4 mM KCl, 0.8 mM MgSO4, 0.8 mM NaH2PO4,
1.2 mM CaCl2, glucose 5.6 mM, and HEPES 4 mM
[pH 7.4]) containing 1% heat-inactivated fetal bovine
serum and 150 μg/ml D-Luciferin. Photon flux was
quantified at room temperature with a SAFAS Xenius
spectrofluorimeter for 1 min or an Orion microplate
luminometer for 10 sec.Sequence analysis
Vpu amino acid sequences were aligned using multiple
sequence alignment with hierarchical clustering (http://
multalin.toulouse.inra.fr/multalin/). Vpu sequences were ob-
tained from the HIV Sequence Database (www.hiv.lanl.gov).
Statistical methods
The activities of vpu alleles were compared using a
two-tailed Student’s t test. The PRISM package version 4.0
(Abacus Concepts, Berkeley, CA) was used for all
calculations.
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Additional file 1: Table S1. Origin of HIV-1, SIVcpz and SIVgor vpu
alleles analyzed.
Additional file 2: Figure S1. Tetherin (upper panel) or CD4
(lower panel) surface expression levels of HeLa cells co-transfected with a
CD4 (lower panel) expression vector and pCGCG plasmids expressing
eGFP alone (eGFPonly) or together with the indicated vpu alleles. A
construct expressing NL4-3 Vpu was used as a positive control.
Additional file 3: Figure S2. Levels of CD4 surface expression levels of
293T cells and HeLa cells transfected with a pCGCG plasmids expressing
eGFP alone (vector) or together with CD4 and on TZM-bl cells stably
expressing CD4. The numbers give the mean fluorescence intensity of
CD4 expression by the transfected eGFP + cell population.
Additional file 4: Figure S3. Interaction of wild-type and chimeric HIV-
1 and SIVcpz/gor Vpu proteins with ß-TrCP and CD4. Interaction of Vpu
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dominant negative mutant of β-TrCP1. Refer to the legend to Figure 6
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